Home
Company
Product
Regulation
China
Data
Exhibition
Interview
中文版
Home
Company
Product
Regulation
China
Data
Exhibition
Interview
中文版
Search

Manx Parliament Expected to Approve 2023 E-Cigarette Product Act

Regulations by 2FIRSTS.ai
Mar.29.2024
Manx Parliament Expected to Approve 2023 E-Cigarette Product Act
The Isle of Man's "2023 e-cigarette Products Act" expected to gain royal approval at the next Tynwald meeting on April 16.

According to a report from iomtoday on March 29th, the "2023 E-Cigarette Products Bill" in the Isle of Man is expected to receive royal approval at the next Tynwald Court meeting scheduled for April 16th (Tuesday).

 

If the bill is passed, it will be illegal for individuals under the age of 18 to purchase e-cigarette products in the Isle of Man starting from mid-April.

 

Last June, the lower house of parliament passed the relevant legislation, and it received final approval from the legislative committee in October.

 

Kate Lord-Brennan, Minister of the Isle of Man Cabinet Office, announced during a session of the House of Keys on Tuesday, March 26th, that the "2023 e-cigarette Products Act" was passed by all departments on December 19, 2023.

 

The Public Prosecution Service has requested a very short turnaround time during the Christmas period to update the legislation based on amendments from the Legislative Council. After completing these updates, the legislation was sent to the Department of Justice on January 11th, and the department has indicated that the legislation is scheduled to receive royal approval in April as planned.

 

References:
[1] Vaping Bill expected to gain royal assent during April's Tynwald sitting
Also Read:
[1] British Association Warns of Illegal Trade Growth Post E-Cigarette Ban
#Europe#Legislation#E-cigarettes#Open system e-cigarettes#Product#Isle of Man

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

China Tobacco Regulation Shift：Policy Updates and Market Impact
China Tobacco Regulation Shift：Policy Updates and Market Impact
22nd Century Positions VLN® Cigarettes for Growth as FDA Considers 0.7 mg/g Nicotine Cap
22nd Century Positions VLN® Cigarettes for Growth as FDA Considers 0.7 mg/g Nicotine Cap
22nd Century Group (Nasdaq: XXII) reported early commercial momentum for its FDA-authorized VLN® very low nicotine cigarettes, distributing approximately 8,800 cartons across 1,700 new U.S. retail outlets in the fourth quarter of 2025, while forecasting expansion to more than 5,000 retail points in 2026.
Business
Feb.24
BENDSTA Urges Prime Minister to Review Bangladesh’s 2025 Tobacco Control Ordinance
BENDSTA Urges Prime Minister to Review Bangladesh’s 2025 Tobacco Control Ordinance
The Bangladesh Electronic Nicotine Delivery System Traders Association (BENDSTA) has urged the prime minister to initiate a comprehensive parliamentary review of the Smoking and Tobacco Products Use (Control) Ordinance, 2025.
Mar.12 by 2FIRSTS.ai
Philip Morris International: Over $20 Billion Invested in the U.S. Since 2022; IQOS ILUMA to Launch Pending FDA Authorization
Philip Morris International: Over $20 Billion Invested in the U.S. Since 2022; IQOS ILUMA to Launch Pending FDA Authorization
Philip Morris International (PMI) said its U.S.-related investments have topped $20 billion since 2022, when it entered the U.S. market through its roughly $19 billion acquisition of Swedish Match. The company also said it plans to launch its heated tobacco product IQOS ILUMA in the United States pending authorization from the U.S. Food and Drug Administration (FDA).
Jan.16 by 2FIRSTS.ai
2Firsts Holds Second PMTA Compliance Training in Shenzhen, Highlighting U.S. Regulatory Framework and Corporate Compliance Capabilities
2Firsts Holds Second PMTA Compliance Training in Shenzhen, Highlighting U.S. Regulatory Framework and Corporate Compliance Capabilities
2Firsts held its second U.S. PMTA compliance training in Shenzhen, providing a systematic overview of the U.S. regulatory framework for e-cigarettes and corporate compliance strategies. Nearly 20 industry professionals from manufacturing, e-liquid and supply-chain companies attended. Participants who passed the exam received compliance certification. Registration for the third training session will open soon, alongside customized corporate training programs.
Mar.09
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
Special Report | Middle East Military Conflict Disrupts Global Air Corridors: Europe-Bound Vape Logistics Defy Seasonal Price Declines, Fuel Cost Risks Emerge
Special Report | Middle East Military Conflict Disrupts Global Air Corridors: Europe-Bound Vape Logistics Defy Seasonal Price Declines, Fuel Cost Risks Emerge
Escalating tensions involving Iran are disrupting air transit routes heavily used for China’s vape exports to Europe, preventing the usual post–Lunar New Year freight rate decline. While Europe-bound capacity reliant on Middle East hubs faces pressure, shipments to the United States remain largely unaffected for now. However, potential jet fuel price increases could broaden cost pressures globally.
Special Report
Mar.02
Related Topics
News Regulation
Related Read
22nd Century Positions VLN® Cigarettes for Growth as FDA Considers 0.7 mg/g Nicotine Cap
22nd Century Positions VLN® Cigarettes for Growth as FDA Considers 0.7 mg/g Nicotine Cap
BENDSTA Urges Prime Minister to Review Bangladesh’s 2025 Tobacco Control Ordinance
BENDSTA Urges Prime Minister to Review Bangladesh’s 2025 Tobacco Control Ordinance
2FIRSTS.ai
Philip Morris International: Over $20 Billion Invested in the U.S. Since 2022; IQOS ILUMA to Launch Pending FDA Authorization
Philip Morris International: Over $20 Billion Invested in the U.S. Since 2022; IQOS ILUMA to Launch Pending FDA Authorization
2FIRSTS.ai
2Firsts Holds Second PMTA Compliance Training in Shenzhen, Highlighting U.S. Regulatory Framework and Corporate Compliance Capabilities
2Firsts Holds Second PMTA Compliance Training in Shenzhen, Highlighting U.S. Regulatory Framework and Corporate Compliance Capabilities
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Special Report | Middle East Military Conflict Disrupts Global Air Corridors: Europe-Bound Vape Logistics Defy Seasonal Price Declines, Fuel Cost Risks Emerge
Special Report | Middle East Military Conflict Disrupts Global Air Corridors: Europe-Bound Vape Logistics Defy Seasonal Price Declines, Fuel Cost Risks Emerge
FOLLOW US ON SOCIAL MEDIA
Contact: info@2firsts.com
Stay up to date.
Submit your email to receive weekly newsletter on the most relevant news of the e-cigarette industry.
© 2026 2FIRSTS. All Right Reserved.
2FIRSTS is only accessible to industry practitioners, researchers, media and other professionals. Access by minors is prohibited.
This website provides services to users outside the Chinese mainland.
English
English
中文